Whereas high galectin-9 expression was associated with reduced survival in lung cancer, increased expression was associated with improved survival in hepatocellular carcinoma, gastric and colorectal cancer and also with a low metastatic potential in breast cancer [17–21]. The gene discussed is LGALS9; the disease is hepatocellular carcinoma.